Allogenic natural killer cell immunotherapy of sizeable ovarian cancer: A case report Corrigendum in /10.3892/mco.2017.1395

Xie,Silun; Chen,Jibing; Zhang,Mingjiie; Wu,Zhengyi

doi:10.3892/mco.2017.1230

Allogenic natural killer cell immunotherapy of sizeable ovarian cancer: A case report

Corrigendum in: /10.3892/mco.2017.1395

Authors:
- Silun Xie
- Jibing Chen
- Mingjiie Zhang
- Zhengyi Wu
View Affiliations

Affiliations: Shenzhen Hank Bioengineering Institute, Shenzhen, Guangdong 518004, P.R. China, Cancer Institute of Fuda Cancer Hospital, Jinan University School of Medicine, Guangzhou, Guangdong 510665, P.R. China
Published online on: April 28, 2017 https://doi.org/10.3892/mco.2017.1230
Pages: 903-906

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Masses are often detected in the abdomen of patients with sizeable ovarian cancer. There are currently no effective treatments available for late-stage ovarian cancer. Immunotherapy is gaining increasing attention worldwide in the clinical setting due to its ability to eliminate tumor cells and its favorable toxicity profile. We herein report the case of a 60-year-old woman who received allogenic natural killer (NK) cell immunotherapy for a sizeable ovarian carcinoma and achieved a noteworthy response. NK cells were isolated from the patient's own peripheral blood mononuclear cells, and the cell numbers were increased to 8-10 billion. The activated cells were expanded ex vivo for 14 days prior to intravenous infusion. After six infusions of NK cell therapy >3 months, the level of carbohydrate antigen 125 decreased significantly (from 11,270 to 580 U/ml). Furthermore, the size of the masses in the abdomen was markedly reduced. Overall, the treatment had few adverse effects and it prolonged patient survival. The present data and the patient response suggest that allogenic NK cell immunotherapy is a promising approach for ovarian cancer, with few treatment‑related adverse effects. The patient received six intravenous infusions of allogenic HANK cells between March, 2015 and June, 2015, but discontinued in October, 2015 and succumbed to the disease in March, 2016 following relapse.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
2	zum B, üschenfelde CM, Hermann C, Schmidt B, Peschel C and Bernhard H: Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res. 62:2244–2247. 2002.PubMed/NCBI
3	Imai C, Iwamoto S and Campana D: Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 106:376–383. 2005. View Article : Google Scholar : PubMed/NCBI
4	Zhang M, Daniel S, Huang Y, Chancey C, Huang Q, Lei YF, Grinev A, Mostowski H, Rios M and Dayton A: Anti-West Nile virus activity of in vitro expanded human primary natural killer cells. BMC Immunol. 11:32010. View Article : Google Scholar : PubMed/NCBI
5	Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 313:1485–1492. 1985. View Article : Google Scholar : PubMed/NCBI
6	Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Krüger C, Manns MP, Greten TF and Korangy F: A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology. 135:234–243. 2008. View Article : Google Scholar : PubMed/NCBI
7	Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, et al: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 348:203–213. 2003. View Article : Google Scholar : PubMed/NCBI
8	Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, et al: Intraepithelial CD8⁺ tumor-infiltrating lymphocytes and a high CD8⁺/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 102:pp. 18538–18543. 2005; View Article : Google Scholar : PubMed/NCBI
9	Liu J, Li H, Cao S, Zhang X, Yu J, Qi J, An X, Yu W, Ren X and Hao X: Maintenance therapy with autologous cytokine-induced killer cells in patients with advanced epithelial ovarian cancer after first-line treatment. J Immunother. 37:115–122. 2014. View Article : Google Scholar : PubMed/NCBI
10	Orange JS: Formation and function of the lytic NK-cell immunological synapse. Nat Rev Immunol. 8:713–725. 2008. View Article : Google Scholar : PubMed/NCBI
11	Zompi S and Colucci F: Anatomy of a murder-signal transduction pathways leading to activation of natural killer cells. Immunol Lett. 97:31–39. 2005. View Article : Google Scholar : PubMed/NCBI
12	Biron CA, Nguyen KB, Pien GC, Cousens LP and Salazar-Mather TP: Natural killer cells in antiviral defense: Function and regulation by innate cytokines. Annu Rev Immunol. 17:189–220. 1999. View Article : Google Scholar : PubMed/NCBI
13	Moretta L, Bottino C, Pende D, Vitale M, Mingari MC and Moretta A: Human natural killer cells: Molecular mechanisms controlling NK cell activation and tumor cell lysis. Immunol Lett. 100:7–13. 2005. View Article : Google Scholar : PubMed/NCBI
14	Ravetch JV and Bolland S: IgG Fc receptors. Annu Rev Immunol. 19:275–290. 2001. View Article : Google Scholar : PubMed/NCBI
15	Farag SS, VanDeusen JB, Fehniger TA and Caligiuri MA: Biology and clinical impact of human natural killer cells. Int J Hematol. 78:7–17. 2003. View Article : Google Scholar : PubMed/NCBI
16	Alderson KL and Sondel PM: Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J Biomed Biotechnol. 2011:3791232011. View Article : Google Scholar : PubMed/NCBI
17	Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, et al: Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 105:3051–3057. 2005. View Article : Google Scholar : PubMed/NCBI
18	Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, Pui CH and Leung W: NKAML: A pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol. 28:955–959. 2010. View Article : Google Scholar : PubMed/NCBI
19	Curti A, Ruggeri L, D'Addio A, Bontadini A, Dan E, Motta MR, Trabanelli S, Giudice V, Urbani E, Martinelli G, et al: Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood. 118:3273–3279. 2011. View Article : Google Scholar : PubMed/NCBI
20	Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN, Rigatos G, Papamichail M and Perez SA: A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother. 59:1781–1789. 2010. View Article : Google Scholar : PubMed/NCBI
21	Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, Jonson AL, Panoskaltsis-Mortari A, Curtsinger J, McKenna D, et al: A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 13:98–107. 2011. View Article : Google Scholar : PubMed/NCBI